BOI.PA
Strong BuyUnloved QualityAI screen passBoiron SA · Healthcare · France · $391M
EUR 18.30 -2.7% · close 7 Oct · scored 9 Oct
Unloved Quality: Strong and cheap; the market has not turned yet.
Read our full research report on BOI.PA (Jun 2026), freeDoes StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Boiron meets all eligibility thresholds with strong factor scores and positive forward-EPS momentum. As a niche healthcare operator, it demonstrates resilient compounding potential in a volatile environment.
ABOUT BOIRON SA
Read
Boiron SA is the world's leading manufacturer of homeopathic medicines, distributing its products in over 50 countries. The company's competitive moat is established by its dominant brand recognition, extensive global distribution network, and specialized manufacturing processes. It operates as the undisputed market leader in the global homeopathic and natural healthcare sector.
FINANCIAL SUMMARY (EUR)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 534.2M | 493.2M | 487.6M | 501.1M | -2.1% | 498.9M |
| EPS (EUR) | 2.57 | 2.06 | 0.65 | 1.88 | -9.9% | 1.52 |
| Shares | 17.4M | 17.4M | 17.4M | 17.4M | -0.1% | 17.4M |
| Debt | 22.2M | 13.7M | 15.0M | 31.5M | 12.4% | 24.0M |
| Equity | 557.6M | 393.7M | 378.1M | 392.8M | -11.0% | — |
| Op CF | 58.7M | 45.5M | 39.5M | 53.2M | -3.2% | 41.1M |
| Inv CF | -15.3M | -22.9M | -18.4M | -23.4M | — | — |
| Fin CF | -27.6M | -198.4M | -27.9M | -24.4M | — | — |
Calmer than 71% of stocks we rank over the past year (31% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BOI.PA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BOI.PA | Boiron SA(you) | $391M | 90 | Strong Buy |
| VETO.PA | Vetoquinol SA | $999M | 96 | Strong Buy |
| IPN.PA | Ipsen S.A. | $13.9B | 95 | Strong Buy |
| LNA.PA | LNA Santé SA | $334M | 91 | Strong Buy |
| AB.PA | AB Science S.A. | $78M | 9 | Strong Sell |
| ALERS.PA | Eurobio Scientific Société anonyme | $289M | 82 | Strong Buy |
| BLC.PA | Bastide Le Confort Médical SA | $170M | 89 | Strong Buy |
| LBIRD.PA | Lumibird SA | $621M | 80 | Buy |
| VIRP.PA | Virbac SA | $2.9B | 89 | Strong Buy |
| CLARI.PA | Clariane SE | $1.6B | 65 | Buy |
Peer medians: ROE -64.2% · P/E 21.9x · Gross margin 72.2%
Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.